{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014751","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.950054+00:00","generated_at":"2026-06-24T03:58:14.432089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CytomX Q2 2022 revenue $18M; cash $228M; restructuring extends runway to 2025","bullets":["Cash and investments $228M at June 30, 2022, down from $305M at Dec 31, 2021.","Total revenue $18M for Q2 2022, up from $16M in Q2 2021; R&D expense $31M (+$5M YoY).","Company restructuring announced July 2022 aims to extend cash runway into 2025.","IND filings planned for CX-801 (IFN alpha-2b) and CX-2051 (EpCAM ADC) in H2 2023.","CX-2029 data update for squamous NSCLC expected Q4 2022; praluzatamab ravtansine also updating Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014751","json":"https://secwatch.observer/filing/0000950170-22-014751.json","markdown":"https://secwatch.observer/filing/0000950170-22-014751.md","text":"https://secwatch.observer/filing/0000950170-22-014751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022014751/0000950170-22-014751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017022014751/ctmx-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:58:14.432089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}